Development of hyperdiploidy starts at an early age and takes a decade to complete

Archive ouverte

Samur, Mehmet | Aktas Samur, Anil | Shah, Parth | Park, Joseph | Fulciniti, Mariateresa | Shammas, Masood | Corre, Jill | Anderson, Kenneth | Parmigiani, Giovanni | Avet-Loiseau, Hervé | Munshi, Nikhil

Edité par CCSD ; American Society of Hematology -

International audience. Abstract Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy are still unclear. Here, we used 72 whole-genome sequencing samples from patients with HMM and identified pre- and post-HMM mutations to define the chronology of the development of hyperdiploidy. An MM cell accumulated a median of 0.56 mutations per megabase before HMM, and for every clonal pre-HMM mutation, 1.21 mutations per megabase accumulated after HMM. This analysis using mutations before and after hyperdiploidy shows that hyperdiploidy happens after somatic hypermutation. Prehyperdiploidy mutations are activation-induced cytidine deaminase and age/clock-like signature driven, whereas posthyperdiploidy mutations are from DNA damage and APOBEC. Interestingly, the first hyperdiploidy event occurred within the first 3 decades of life and took a decade to complete. Copy number changes affecting chromosomes 15 and 19 occurred first. Finally, mutations before initiating event affected chromosomes at different rates, whereas post–initiating event mutational processes affect each chromosome equally.

Consulter en ligne

Suggestions

Du même auteur

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. Abstract High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect ...

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviv...

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. PURPOSE Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequ...

Chargement des enrichissements...